by Eric Christianson | Jul 21, 2024 | Psychiatry and Addiction Medication and Disease State Clinical Pearls
Paroxetine is from the family of SSRIs (selective serotonin reuptake inhibitors. It has been around for a long time and is indicated for depression, anxiety, and many other psychiatric indications just like other SSRIs. It doesn’t get much love from healthcare...
by Eric Christianson | Nov 26, 2023 | Polypharmacy Cases And The Prescribing Cascade
In this case, I outline a unique situation involving stimulants and elderly patients. I outline some of the potential complications and contributions to the prescribing cascade. A 76-year-old female resides in an assisted living. She has a history of ADHD, anxiety,...
by Eric Christianson | Mar 18, 2020 | Clinical Pharmacy News and New Drug Updates
I’m seeing this article all over the place recommending to avoid NSAIDs in patients who have an infection with the new COVID-19 coronavirus. My question is, where’s the evidence? The only thing I can find is that it was based upon is a scientific theory as...
by Eric Christianson | Sep 15, 2019 | Clinical Guideline Updates For Pharmacists
The Beers Criteria was updated in 2019. Of the numerous updates, I wanted to pull out my top 5 clinically relevant Beers Criteria updates. It is important to note that there were many more updates, but I wanted to share some of the most clinically important updates....
by Eric Christianson | Sep 1, 2019 | Medication and Disease State Clinical Pearls For Pharmacists, Psychiatry and Addiction Medication and Disease State Clinical Pearls
Benzodiazepines are on the Beers criteria. They can have significant adverse effects like sedation, confusion, the risk for dependence, and increased fall risk. We like to avoid benzodiazepines if we can, but what if we do feel that it is necessary (i.e. hospice or...
